Ionis Pharmaceuticals (IONS) announced that Ionis’ and AstraZeneca’s (AZN) Wainzua has been recommended for approval by the Committee for Medicinal Products for Human Use, or CHMP, in the European Union, or EU, for the treatment of hereditary transthyretin-mediated amyloidosis in adult patients with stage 1 or stage 2 polyneuropathy, commonly referred to as hATTR-PN or ATTRv-PN. If approved by the European Commission, Wainzua will be the only approved medicine in the EU for the treatment of ATTRv-PN that can be self-administered monthly via an auto-injector.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IONS:
- Ionis Pharmaceuticals price target lowered to $65 from $70 at Guggenheim
- Ionis Pharmaceuticals to present data on donidalorsen at ACAAI
- Ionis announces U.S. FDA granted Fast Track Designation for zilganersen
- Biotech Alert: Searches spiking for these stocks today
- Oracle reports Q1 beat, EU says Apple must pay: Morning Buzz
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
